Biomarker ID | 475 |
PMID | 19652763 |
Year | 2009 |
Biomarker | ABLIM3 (actin binding LIM protein family, member 3); AOX1 (aldehyde oxidase 1); CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)); DSCR1 (Down syndrome critical region gene 1); GLRX (glutaredoxin (thioltransferase)); IGFBP4 (insulin-like growth factor binding protein 4); MT1B (metallothionein 1B); MT1E (metallothionein 1E); MT1F (metallothionein 1F); MT1H (metallothionein 1H); C1QB (complement component 1, q subcomponent, B chain); CYB5R3 (cytochrome b5 reductase 3); DARC (Duffy blood group, chemokine receptor); DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)); F13A1 (coagulation factor XIII, A1 polypeptide); FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)); G0S2 (G0/G1switch 2); GAS6 (growth arrest-specifi c 6); IFITM2 (interferon induced transmembrane protein 2 (1–8D)); ITGA1 (integrin, alpha 1); MAP4 (microtubule-associated protein 4); MT1A (metallothionein 1A); MT2A (metallothionein 2A); PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase); PROS1 (protein S (alpha)); RBPMS (RNA binding protein with multiple splicing); RDX (Radixin); RNF11 (ring finger protein 11); S100A8 (S100 calcium binding protein A8); SERINC1 (serine incorporator 1); SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)); STOM (stomatin); TGFBR3 (transforming growth factor, beta receptor III); TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)); WDR47 (WD repeat domain 47) |
Biomarker Basis | Expression Based |
Biomolecule | mRNA |
Source | Tissue |
Subjects | Humans |
Regulation | Downregulated: ABLIM3 (actin binding LIM protein family, member 3) [1.6 fold]; AOX1 (aldehyde oxidase 1) [2.6 fold]; CES1 (carboxylesterase 1 (monocyte/macrophage serine esterase 1)) [1.7 fold]; DSCR1 (Down syndrome critical region gene 1) [1.6 fold]; GLRX (glutaredoxin (thioltransferase)) [1.7 fold]; IGFBP4 (insulin-like growth factor binding protein 4) [2.5 fold]; MT1B (metallothionein 1B) [2.3 fold]; MT1E (metallothionein 1E) [1.9 fold]; MT1F (metallothionein 1F) [2.3 fold]; MT1H (metallothionein 1H) [2.4 fold]; C1QB (complement component 1, q subcomponent, B chain) [1.4 fold]; CYB5R3 (cytochrome b5 reductase 3) [1.4 fold]; DARC (Duffy blood group, chemokine receptor) [2.9 fold]; DUSP3 (dual specifi city phosphatase 3 (vaccinia virus phosphatase VH1−related)) [1.4 fold]; F13A1 (coagulation factor XIII, A1 polypeptide) [2.1 fold]; FEZ1 (fasciculation and elongation protein zeta 1 (zygin I)) [1.6 fold]; G0S2 (G0/G1switch 2) [2.2 fold]; GAS6 (growth arrest-specifi c 6) [2 fold]; IFITM2 (interferon induced transmembrane protein 2 (1–8D)) [2 fold]; ITGA1 (integrin, alpha 1) [1.4 fold]; MAP4 (microtubule-associated protein 4) [1.6 fold]; MT1A (metallothionein 1A) [2.6 fold]; MT2A (metallothionein 2A) [2.5 fold]; PCMT1 (protein-L-isoaspartate (D-aspartate) O-methyltransferase) [1.3 fold]; PROS1 (protein S (alpha)) [1.7 fold]; RBPMS (RNA binding protein with multiple splicing) [2.4 fold]; RDX (Radixin) [1.4 fold]; RNF11 (ring finger protein 11) [1.4 fold]; S100A8 (S100 calcium binding protein A8) [2.3 fold]; SERINC1 (serine incorporator 1) [1.5 fold]; SERPING1 (serpin peptidase inhibitor, clade G (C1 inhibitor), member 1, (angioedema, hereditary)) [2.2 fold]; STOM (stomatin) [1.8 fold]; TGFBR3 (transforming growth factor, beta receptor III) [1.7 fold]; TGM2 (transglutaminase 2 (C polypeptide, protein-glutamine-gamma-glutamyltransferase)) [1.8 fold]; WDR47 (WD repeat domain 47) [1.5 fold] |
Odds Ratio/Hazard Ratio/Relative Risk | NA |
Effect on Pathways | NA |
Experiment | Tumor Vs Adjacent To Tumor |
Type of Biomarker | Diagnostic |
Cohort | 148 patients such as 23 were organ donors, 59 adjacent to Tumor, and 66 Tumor samples were included. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | Validation Set: 93.9% |
Level Of Significance | p=0.05 |
Method Used | Immunohistochemistry |
Clinical | No |
Remarks | Using Prostate cancer as the training set, Liver samples were predicted with 97.7% accuracy, Lung cancer as 94.5% accuracy and Bladder cancer with 88.3% accuracy |
Clinical Trial Number | NA |
Degree Of Validity | Validated on independent patient dataset |
Technical Name | NA |